Patients with advanced EGFR-mutated NSCLC progressing on first and second generation EGFR TKIs without a T790M resistance mutation or patients progressing on osimertinib regardless of line of therapy and who have a MET amplification should be considered for clinical trials evaluating MET inhibitors. Here, EGFR is linked to non-small cell lung carcinoma.